Product Description
Phentolamine is an alpha-Adrenergic Blocker. Phentolamine is a synthetic imidazoline with alpha-adrenergic antagonist activity. As a competitive alpha-adrenergic antagonist, phentolamine binds to alpha-1 and alpha-2 receptors, resulting in a decrease in peripheral vascular resistance and vasodilatation. This agent also may block 5-hydroxytryptamine (5-HT) receptors and stimulate release of histamine from mast cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Phentolamine)
Mechanisms of Action: ADR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Oral, Subcutaneous, Transdermal, Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Canada | China | Denmark | Egypt | France | Germany | Greece | Ireland | Italy | Korea | Malta | New Zealand | Norway | Portugal | Slovenia | South Africa | Spain | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: ULB Erasme
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Ocuphire Pharma presented P3 Pupil Disorders results on 2024-09-30 for Phentolamine
- Clinical Outcomes Reported - Ocuphire Pharma announced they will present P3 Presbyopia results in YE25 for Phentolamine
Highest Development Phases
Phase 3: Night Blindness|Presbyopia|Vision Disorders|Vitamin A Deficiency
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07140783 |
LYNX-3 | P3 |
Recruiting |
Vitamin A Deficiency|Vision Disorders |
2026-03-01 |
15% |
2025-08-27 |
Primary Endpoints|Treatments |
NCT06542497 |
VEGA-3 | P3 |
Active, not recruiting |
Presbyopia |
2025-10-30 |
12% |
2025-03-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06349759 |
LYNX-2 | P3 |
Active, not recruiting |
Night Blindness |
2025-04-17 |
16% |
2025-07-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05646719 |
VEGA-2 | P3 |
Completed |
Presbyopia |
2023-10-11 |
11% |
2025-06-04 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/03/2026 |
News Article |
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 |
|
02/02/2026 |
News Article |
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 |
|
01/27/2026 |
News Article |
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa |
|
01/08/2026 |
News Article |
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts |